- Home
- OCUL vs TRVI Comparison
OCUL vs TRVI Comparison
Compare OCUL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | TRVI |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OCUL | TRVI |
|---|---|---|
| Price | $8.26 | $13.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $23.56 | $21.55 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,990,000.00 | N/A |
| Revenue This Year | $7.93 | N/A |
| Revenue Next Year | $96.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.48 | N/A |
| 52 Week Low | $6.23 | $5.41 |
| 52 Week High | $16.44 | $16.12 |
Technical Indicators
Market Signals| Indicator | OCUL | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 43.10 |
| Support Level | $7.62 | $13.12 |
| Resistance Level | $9.93 | $13.55 |
| Average True Range (ATR) | 0.46 | 0.57 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 24.47 | 15.34 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.